69 articles - From Friday Jun 20 2025 to Friday Jun 27 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Aliment Pharmacol Ther |
|---|
Expert Position Statement: Defining the Role of Intestinal Ultrasound in Assessing Constipation and Faecal Loading. The expert panel considered intestinal ultrasound an appropriate modality for evaluating constipation and faecal loading. Further prospective research is required, especially in adult patients, to define sonographic metrics of luminal contents to broaden its application in the assessment of functional gastrointestinal disorders. |
| Gastrointest Endosc |
| Gut |
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. These guidelines are intended to support clinical decision-making but are not prescriptive, recognizing that individual clinical scenarios may warrant tailored approaches. Further research may inform future revisions as new evidence emerges. |
meta-analyses and systematic reviews
| Endoscopy |
|---|
Performance of Three Major Techniques for Endoscopic Submucosal Dissection: A Systematic Review and Network Meta-analysis. Both Tu-ESD and Tr-ESD are effective and safe dissection methods compared to C-ESD. Given that different ESD techniques offer certain advantages, the choice of technique should be tailored to the specific clinical scenario. |
| Gastrointest Endosc |
A COMPARISON OF TECHNICAL AND CLINICAL SUCCESS BETWEEN LESSER AND GREATER CURVATURE APPROACHES IN GASTRIC PERORAL ENDOSCOPIC MYOTOMY: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS. G-POEM is associated with high rates of technical and clinical success, which did not differ based on greater curvature and lesser curvature approaches. GCSI scores at 3-6 months were lower in the GC group, but mild adverse events and LOS were higher. Further randomized trials are needed to determine whether outcomes differ by the approach. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource. Severe myelosuppression was associated with NUDT15 variant allele carriage (11.3% vs 0.95%; p 1 NUDT15 variant allele and in patients with both NUDT15 and TPMT variant alleles. In patients with a single NUDT15 variant allele, we recommend thiopurine dose reduction (< 1 mg/kg/day) and intensified blood test monitoring. |
Combined Lyon and Milan Scores Predict Gerd Management Outcome Better Than Either Score Alone or Their Individual Components. The Lyon and Milan scores outperformed AET and DeMeester scores in predicting outcomes in GERD patients. When concordant, they provide optimal predictive accuracy, guiding escalation of therapy. |
| Am J Gastroenterol |
Effect of second sigmoid colon intubation during colonoscopy on adenoma detection rate in overweight and obese patients: A prospective randomized controlled trial. Using a second intubation of the sigmoid colon can effectively enhance the detection rate of sigmoid colon adenomas and polyps. |
Long-term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. Seladelpar demonstrated durable improvements in cholestatic biomarkers and pruritus in patients with PBC with up to 2 years of treatment and remained overall safe with long-term use. |
Vonoprazan High-dose Dual, Vonoprazan Triple and Rabeprazole Reverse Hybrid Therapies for First-line Treatment of H. pylori Infection: A Multicenter Randomized Trial. Vonoprazan triple therapy and rabeprazole reverse hybrid therapy are preferable to vonoprazan dual therapy for first-line treatment of H. pylori infection. |
| Clin Gastroenterol Hepatol |
Cost-effectiveness of novel noninvasive screening tests for colorectal neoplasia. FIT was the most cost-effective strategy for preventing CRC cases and deaths. At real-world adherence of 60%, mt-sRNA demonstrated the greatest clinical benefit and was more cost-effective than other molecular strategies. |
Dietary patterns are associated with variations in the global prevalence and severity of Rome IV Irritable Bowel Syndrome. Dietary patterns adjusted by age, country, and religion are associated with the global prevalence and severity of IBS. Further studies are required to investigate population-specific dietary preferences and acceptability of dietary interventions for IBS. |
External validation of the GOLDEN model for predicting HBsAg loss in non-cirrhotic chronic hepatitis B patients with interferon-alpha based therapy. GOLDEN model is a robust tool for predicting HBsAg loss or decline in IFN-α-treated CHB patients, offering valuable support for clinicians in developing personalized, effective management strategies for CHB patients. |
| Endoscopy |
Endoscopic biopsy techniques in Barrett esophagus patients: a multidesign study. BE surveillance biopsies should be taken with the single-biopsy method and turn-and-suction technique to increase biopsy size. BE surveillance biopsies should be taken with the single-biopsy method and turn-and-suction technique to increase biopsy size. |
Endoscopic papillectomy for laterally spreading lesions of the papilla - a propensity score matched analysis. LSL can be safely resected by EP, though repeated interventions are necessary to achieve complete resection. The higher risk of recurrence in LSL necessitates a vigilant surveillance strategy. |
Evaluation of an improved computer-aided detection system for Barrett's neoplasia on real-world imaging conditions. Based on several key improvements, CADe 2.0 demonstrated increased detection rates and better robustness to data heterogeneity, making it ready for clinical implementation. |
| Gastroenterology |
Whole food diet induces remission in children and young adults with mild-moderate Crohn's disease and is more tolerable than exclusive enteral nutrition: a randomized controlled trial. T&H demonstrated better tolerability than EEN for inducing remission in mild-to-moderate CD, while positively affecting the microbiome (TASTI-MM, NCT#04239248). |
| Gastrointest Endosc |
COMPARISON OF FULLY COVERED SELF-EXPANDABLE METAL STENTS WITH AND WITHOUT ANTI-MIGRATION FINS FOR THE MANAGEMENT OF DISTAL MALIGNANT BILIARY OBSTRUCTION. FCSEMS and FCSEMS-AF have similar performance characteristics at 6 months, however FCSEMS were more likely to migrate and had similar occlusion risk after stent length adjustment. These findings can provide insight into current limitations and help guide future stent design. |
| Gut |
Extracellular vesicle-induced lipid dysregulation drives liver premetastatic niche formation in colorectal cancer. Inhibition of FA synthesis in CRC cells with high metastatic potential reduces hepatic lipid accumulation and subsequent metastasis, highlighting a new strategy for preventing liver metastasis. |
Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold. Serum HBsAg levels <100 IU/mL effectively identify patients with inactive CHB with negligible HCC risk and limited viral activity, which is important in optimising surveillance strategies and defining partial HBV cure. |
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. HCC surveillance should be offered to patients with MASLD with FIB-4 ≥3.25 or LSM ≥20 kPa. When a two-step approach is adopted, LSM ≥15 kPa in patients with increased FIB-4 predicts a high HCC risk. |
Results of endoscopic intermuscular dissection for deep submucosal invasive rectal cancer: a three-year follow-up study. Despite the challenges associated with accurate preoperative staging, EID followed by active surveillance may offer a viable alternative to radical surgery for patients with low- and intermediate-risk rectal D-SMIC, avoiding rectal surgery in most cases while maintaining oncological safety. |
Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial. Rice-derived HSA is non-inferior to plasma-derived HSA in efficacy and safety. This finding should be confirmed in phase 3 trial. |
| Hepatology |
Call to action - pediatric MASLD requires immediate attention to curb health crisis. We provide clear steps to address this public health emergency by promoting awareness campaigns, educating and empowering patients and families, addressing barriers including access to care, nutritional and exercise support programs, establishing multidisciplinary care, launching community initiatives, and conducting clinical trials in pediatric MASLD for an age-based evaluation of novel diagnostic and therapeutic options. We conclude by highlighting the urgent need for comprehensive public health policies to control the tide of pediatric MASLD and call upon stakeholders to act now. |
Dissecting liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure. Our findings provide a comprehensive immune profile in ACLF and highlight ANXA1 as a potential therapeutic target for resolving immune dysregulation and improving outcomes in ACLF. |
Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders. Like major conjugated BAs, MABAs are transferred from the gut, where they are produced, to the bile of patients with hepatopancreatobiliary diseases, suggesting gut dysbiosis that favors species generating these compounds. |
Health IT interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial. In a multicenter RCT of 464 cirrhosis inpatients and their caregivers across several practice settings, the Patient Buddy App was associated with lower avoidable readmissions at 30 days post-discharge compared to standard of care. |
Multimodal transcriptomics identifies metallothionein as a novel pathway in primary sclerosing cholangitis. Combinatorial spatial and high-resolution single-nuclei transcriptomics on the largest number of PSC liver explants to date revealed metallothionein as a novel PSC pathway that could be interrogated in future studies aiming to develop effective therapeutic interventions for PSC. |
Tertiary lymphoid structures in hepatocellular carcinoma: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy. The TLS may be associated with significantly longer recurrence-free and overall survival. This association may reflect synergy between TLS and adjuvant PD-1 inhibitor therapy in activating anti-tumor immune responses within tumors. |
Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis. In CHB patients with concurrent HS, T2DM was an independent factor associated with significant fibrosis, HBeAg+ with hepatic inflammation, and BMI with moderate-to-severe steatosis, suggesting that both viral and metabolic control are crucial in the management of CHB patients with HS. |
| J Hepatol |
Bile acids engage the SIPR-STAT3 signaling axis to modulate regulatory T cell responses in fibrosing cholangiopathies. BAs repress Treg suppressor function, polarize Tregs towards a Th17 phenotype, and thus constrain their capacity to protect from immune mediated cholangiocyte injury. Impact and implications This research examines the role of CD4 lymphocytes in controlling bile duct epithelial injury in fibrosing cholangiopathies, with potential implications for developing targeted therapies for biliary atresia and primary sclerosing cholangitis. Using single cell genomics, functional assays, and complementary mouse models of sclerosing cholangitis, mechanisms by which chenodeoxycholic acid derived bile acids determine polarization and suppressor functions of CD4 lymphocytes were investigated. Reduction of hepatic bile acid concentration with IBAT inhibitor, antagonizing STAT3 in CD4 lymphocytes, or blocking of S1P receptors boost hepatic regulator T cells in experimental sclerosing cholangitis and protect from cholestatic liver injury. The preclinical studies will inform future clinical trials in affected patients. |
Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease. TRE effectively reduces hepatic steatosis in MASLD, with comparable benefits on weight loss, body composition, and metabolic parameters as CR. This approach may serve as a practical dietary strategy for MASLD management. |
Glucagon controls obesity-specific energy expenditure via persistent cAMP/PKA signaling. These findings provide the molecular basis for GCG-induced energy expenditure and metabolic benefits and suggest the phenotypic segregation of cAMP/PKA-dependent and independent effects. Impact and implications This study provides fundamental mechanistic insights into GCG pharmacology with direct clinical implications. The obesity-specific enhancement of energy expenditure by GCGR agonist substantiates the superior efficacy of GCGR/glucagon-like peptide-1 receptor (GLP-1R) dual agonists in individuals with obesity compared to GLP-1R mono-agonists. Importantly, differential PDE4 expression patterns may provide a molecular basis for the variable weight-loss responses to GCG-based agonists, identifying PDE4 inhibition as a potential strategy to restore efficacy in GCG-non-responders. Furthermore, the PDE4-overexpression model preserved the lipid-clearing capacity of GCGR agonist while attenuating hyperglycemic risk, demonstrating a translatable strategy to optimize the safety-efficacy profile of GCG-based therapies for cardio-renal-metabolic diseases such as obesity and MASH. |
Impact of first and further decompensation in patients with compensated ACLD due to MASLD. The first and further decompensations represent tipping points in the clinical course of patients with cACLD due to MASLD, increasing 18.9-times and additionally 1.52-times the cause-specific hazard of LR-D. HCC is an independent predictor of LR-D in patients with cACLD due to MASLD, resulting in an additional cause-specific hazard of LR-D when associated with both first and further decompensation. |
Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD. Our findings uncover a novel immunometabolic axis that serves as a functional barrier for MAIT cell-mediated anti-cancer immunity and could be exploited for enhancement of immunotherapy. IMPACT AND IMPLICATIONS ; This study identifies a novel immunometabolic axis by which polyunsaturated fatty acids (PUFAs) accumulating in MASLD liver tissue drive MAIT cell dysfunction through lipid peroxide-induced metabolic exhaustion and ferroptosis, thereby impairing their anti-tumour activity. These findings reveal how MASLD creates an immune-permissive environment that may facilitate HCC development and -progression. Targeting the PUFA-lipid peroxide axis could restore MAIT cell function and enhance current immunotherapeutic anti-cancer strategies. |
Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases. The HBV-CRA is an easy-to-use assay that identifies immune profiles associated with HBsAg clearance in AHB and differentiates CHB patients based on antiviral T cell function. Importantly, distinct HBV-specific T cell cytokine patterns were detected independently of conventional clinical disease phases, suggesting that stratifications of CHB patients for immunotherapeutic interventions should be guided by HBV-CRA. Impact and implications Challenges in collecting anti-HBV immune biomarkers from chronic hepatitis B (CHB) patients have led us to develop an easy-to-use assay (HBV-CRA) designed to quantify virus-specific T cell function in the patients' whole blood. We show that HBV-CRA can identify immune profiles associated with HBsAg clearance in AHB and reveal functional T cell heterogeneity among CHB patients that is not captured by standard clinical classifications. By offering a scalable, point-of-care immune monitoring tool, HBV-CRA could support the development and implementation of personalized immunotherapeutic strategies in CHB management. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
Review Article: Drug-Induced Liver Injury Associated With Antibody-Based Therapies in Haematologic Malignancies. DILI remains a major challenge in the use of antibody-based therapies for haematologic malignancies. While progress has been made in understanding risk factors and management strategies, further research is essential to optimise patient care and balance therapeutic efficacy with liver toxicity risks. |
| Clin Gastroenterol Hepatol |
| J Hepatol |
Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases. Emerging senolytic therapies that target senescent cells and hepatic fibrosis are highlighted alongside regulatory CAR-T cells that induce liver-specific immune tolerance in transplantation. Future and ongoing research is reviewed that seeks to enhance the specificity, efficacy, and safety of CAR-based therapies as "living drugs" that facilitate targeted, sustained, and personalized interventions for liver diseases. |
History and prospects of bile acid therapies. Development of new drugs interacting with the enterohepatic bile acid circulation has attracted attention for rare genetic pediatric disorders. The present review describes the current status and future prospects of bile acid-based therapies for hepatobiliary diseases of adults, children and during pregnancy on the basis of historical developments over centuries and millennia. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Gastroenterology |
| Gastrointest Endosc |
| Gut |
| J Hepatol |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Gastroenterology |
| Gut |
| J Hepatol |